Lung Cancer | Specialty

Jänne Explains Gefitinib's Role in EGFR-Mutant NSCLC

August 5th 2015

Pasi A. Jänne, MD, PhD, discuses the impact of gefitinib's reentry into the US market as a first-line treatment for patients with metastatic non–small cell lung cancer.

Clovis Completes Rociletinib NDA for EGFR T790M-positive NSCLC

August 3rd 2015

A new drug application has been submitted for rociletinib as a treatment for patients with EGFR T790M-positive metastatic non–small cell lung cancer following prior administration of an EGFR TKI.

New Trial Designs Hope to Enhance Biomarker Discovery

August 3rd 2015

Clinical trial designs are undergoing a dramatic transformation geared toward the discovery and validation of new predictive biomarkers.

Two FDA Approvals, BRAF/MEK Breakthrough Status in NSCLC, and More

August 3rd 2015

Targeting HER2 in NSCLC Remains Work in Progress

August 2nd 2015

Corey Langer, MD, discussed the therapeutic potential for anti-HER2 agents in non–small cell lung cancer in a presentation at the 2015 International Lung Cancer Congress.

Immune Checkpoint Combination Strategies Evolving in NSCLC

August 1st 2015

A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.

Dr. Bunn Discusses the Need to Study Drug Combinations in Lung Cancer

August 1st 2015

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

Translational Advances Deliver Precision Medicine to NSCLC

July 31st 2015

Paul Bunn, MD, discussed the latest translational advances in NSCLC at the 2015 International Lung Cancer Congress.

Explosion in Next-Generation Agents on Horizon in NSCLC

July 31st 2015

Highly effective next-generation therapies are currently in development for patients with oncogene-driven non–small cell lung cancer, specifically those with alterations in EGFR, ALK, ROS1, NTRK, or a variety of other gene.

Two Positive Phase III RCC Studies, Nivolumab Approved for NSCLC in Europe, and More

July 24th 2015

Dabrafenib/Trametinib Combo Receives Breakthrough Designation for NSCLC

July 23rd 2015

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib as a potential treatment for patients with BRAFV600E-mutant non-small cell lung cancer.

Nivolumab Gains European Approval for Squamous NSCLC

July 20th 2015

The European Commission has approved nivolumab as a treatment for patients with locally advanced or metastatic squamous non–small cell lung cancer following prior chemotherapy.

Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More

July 19th 2015

Frontline Gefitinib Approved in EGFR-Positive NSCLC

July 13th 2015

The FDA approved gefitinib for the frontline treatment of patients with metastatic, EGFR-positive non-small cell lung cancer.

Dr. Temel on Anorexia and Cachexia in NSCLC

July 13th 2015

Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.

Adding Atezolizumab to Chemotherapy Shows Promise in NSCLC

July 10th 2015

Stephen Liu, MD, discusses the results and purpose of the uniquely designed trial examining atezolizumab in combination with platinum-based doublet chemotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

ODAC Supports Necitumumab for Squamous NSCLC

July 9th 2015

ODAC supported the approval of necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer.

FDA Approval Sought for Rociletinib in EGFR T790M-Positive NSCLC

July 2nd 2015

Rolling submission of a new drug application for rociletinib has been initiated for patients with EGFR T790M-positive metastatic non–small cell lung cancer following prior treatment with an EGFR-targeted therapy.

Importance of Molecular Classification

July 1st 2015

Cost Effectiveness of Gene Expression Testing

July 1st 2015